UK Stocks-Factors to watch on September 29

By Reuters News

- Britain's FTSE 100 .FTSE index is seen opening higher on Tuesday, with futures up 0.1%.

* ASTRAZENECA: AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up. Separately, HUTCHMED (China) said that AstraZeneca had applied to the US FDA for approval of the ORPATHYS-TAGRISSO combination to treat patients with advanced lung cancer.

* INFLATION: British shop price inflation slowed slightly in September despite rising cost pressures on retailers from the Iran war, according to a survey from the British Retail Consortium, which urged the government to do more to help.

* ENERGY: Andy Burnham will announce plans to create Great British Grid, a publicly owned body within Great British Energy, during his Labour Party conference speech, the party said on Monday.

* OIL: Oil prices rose for a second successive session as concern over Middle East supply disruption from the US-Iran conflict outweighed signs of recovering crude exports from the region.

* GOLD: Gold inched up but hovered near a more than seven-week low as concerns that the Federal Reserve may keep interest rates higher for longer outweighed investor focus on upcoming US economic data.

* METALS: Copper advanced after a sharp selloff in the previous session, even as a strong dollar, elevated oil prices and concerns about Chinese demand kept a cap on bullish sentiment.

* The UK blue-chip index .FTSE closed down 0.10% on Monday as weaker metal prices and rising bond yields kept risk appetite in check.

* UK CORPORATE DIARY:

Close Brothers

CBRO.L

FY results

S&U PLC

SUS.L

HY results

A.G. Barr

BAG.L

HY results

Card Factory

CARDC.L

HY results

* For more on the factors affecting European stocks, please click on: LIVE/

TODAY'S UK PAPERS
> Financial Times PRESS/FT
> Other business headlines PRESS/GB

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.